- cafead   Sep 16, 2024 at 11:12: AM
via Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat.
Looking to assess whether Ocaliva met its postmarketing requirements after a 2016 accelerated approval in the autoimmune disease primary biliary cholangitis (PBC), the FDA’s council of outside experts nearly unanimously rejected Intercept’s hopes for a full approval of its farnesoid X receptor agonist.
article source
Looking to assess whether Ocaliva met its postmarketing requirements after a 2016 accelerated approval in the autoimmune disease primary biliary cholangitis (PBC), the FDA’s council of outside experts nearly unanimously rejected Intercept’s hopes for a full approval of its farnesoid X receptor agonist.
article source